MENU
Friday, February 25th, 2:00PM EDT

Clinical and Institutional Practice Update: Optimization of Anti-Xa Lab Test Utilization Across Care Centers

Sponsored by: Diagnostica Stago, Inc.
Speaker

Abstract
Clinical and Institutional Practice Update: Optimization of Anti-Xa Lab Test Utilization Across Care Centers
 

Perhaps more than any other area of clinical medicine, anticoagulation management laboratory data are evaluated hourly by healthcare systems in the inpatient setting and daily in the outpatient setting to provide efficacy, safety, and markers of clinical success for drugs and disease states relating to embolic disease. These laboratory data provide answers that in their absence, or a failure of understanding, can result in patient harm or death. Accordingly, laboratory staff, pharmacists, hematologists, and pathologists supervising these efforts need concise, evidence-based, expert-endorsed information upon which to predicate their ability to understand and provide the same. This continuing education activity will discuss these issues, allowing participants to provide clinical laboratory data with the highest integrity and service to their patients.

 
Learning Objectives
  • Describe differences between unfractionated heparin (UFH), low-molecular-weight-heparin (LMWH) and direct-oral anticoagulants (DOACs) and impact on laboratory monitoring
  • Identify advantages and disadvantages of surrogate markers to monitor and measure efficacy of UFH LMWH and DOACs, focusing on reference ranges and limitations of the traditional surrogate markers and benefit of anti-Xa monitoring
  • Present management strategies for appropriate use of anti-Xa heparin level determinations
  • Highlight case studies featuring situations for which direct oral anticoagulant measurement assisted with patient management
 
 
 

You May Also Like
Loading Comments...